# Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)

> **NCT05255666** · PHASE2 · WITHDRAWN · sponsor: **Washington University School of Medicine**

## Conditions studied

- Triple Negative Breast Cancer
- Brain Metastases

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Liposomal Irinotecan

## Key facts

- **NCT ID:** NCT05255666
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-07-31
- **Primary completion:** 2027-01-31
- **Final completion:** 2030-01-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No drug
- **Last updated:** 2023-07-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05255666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05255666, "Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05255666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*